肝细胞癌Advp53AAVHGFK1联合转基因治疗的临床疗效和预后分（基础医学范文）.docVIP

肝细胞癌Advp53AAVHGFK1联合转基因治疗的临床疗效和预后分（基础医学范文） 文档信息 属性： F-00NN25，doc格式，正文8202字。质优实惠，欢迎下载！ 适用： 作为文章写作的参考文献，解决如何写好实用应用文、正确编写文案格式、内容摘取等相关工作。 作者： 佚名 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 搞要 1 关键字：Adv-p53；AAV-HGFK1；转基因治疗；肝细胞癌；预后 2 2 结果 5 3 讨论 6 [参考文献] 8 论文原创声明（模板） 12 论文致谢（模板） 12 正文 肝细胞癌Advp53AAVHGFK1联合转基因治疗的临床疗效和预后分（基础医学范文） 搞要 摘要：目的分析肝细胞癌Adv-p53、AAV-HGFK1联合转基因治疗的临床疗效和预后。方法选取我科2009年1月～2012年1月进展期肝癌患者共50例，随机分为重组腺相关病毒-肝细胞生长因子第l螺旋区（recombinantadeno-associatedvirus-kringle1domainofhepatocytegrowthfactor）AAV-HGFK1+Adv-p53组和AAV-HGFKI组。比较两组患者治疗后肝穿刺活检标本新生微血管和凋亡细胞率、临床疗效、复发率、生存率。结果AAV-HGFK1+Adv-p53组治疗后第14天、第21天的新生微血管数量显著低于AAV-HGFK1组，凋亡细胞率显著高于AAV-HGFK1组（）。AAV-HGFK1+Adv-p53组1年、3年复发率显著低于AAV-HGFK1组，1年、3年生存率显著高于AAV-HGFK1组（P）。结论Adv-p53、AAV-HGFK1联合治疗进展期肝细胞癌疗效优于AAV-HGFK1单独治疗，预后更佳 关键字：Adv-p53；AAV-HGFK1；转基因治疗；肝细胞癌；预后 [中图分类号] [文献标识码] A [文章编号] 1673-9701（2015）26-0008-04 Clinical efficacy and prognosis of Adv-p53， AAV-HGFK1 combined gene therapy for HCC ZHANG Fabiao FANG Zheping Department of Hepatobiliary Surgery， Taizhou Hospital in Zhejiang Province， Linhai 317000， China [Abstract] Objective To analyze the clinical efficacy and prognosis of Adv-p53， AAV-HGFK1 combined gene therapy for HCC. Methods Fifty patients with advanced liver cancer in our department from January 2009 to January 2012 were randomly divided into AAV-HGFK1+Adv-p53 group and AAV-HGFK1 group. The liver biopsy specimens’ microvessel and apoptosis rate， clinical efficacy and relapse rate were compared in two groups of patients. Results The number of microvessels in AAV-HGFK1+Adv-p53 group 14 days and 21 days was significantly lower than AAV-HGFKI group. The apoptosis rate was significantly higher than that of AAV-HGFK1 group（）. The 1，3-year recurrence rate in the AAV-HGFK1+Adv-p53 group was significantly lower than AAV-HGFK1 group， the 1，3-year survival rate was significantly higher than that of AAV-HGFK1 group（P）. Conclusion Adv-p53， AAV-HGFK1 combination therapy for advanced hepatocellular carcinoma is mor